Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

Cancer

Volumn 92, Issue 7, 2001, Pages 1759-1768

  Blum, Joanne L ^a,b   Dieras, Véronique ^c   Russo, Patricia Mucci Lo ^d   Horton, John ^e   Rutman, Olga ^f   Buzdar, Aman ^g   Osterwalder, Bruno ^h  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c INSTITUT CURIE   (France)

^d HARPER UNIVERSITY HOSPITAL   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f HOFFMANN LA ROCHE INC   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Breast carcinoma; Capecitabine; Oral fluoropyrimidine; Taxane pretreated

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SYNDROME; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT FAILURE;

EID: 0035476911     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A     Document Type: Article

References (27)

1. Treatment of metastatic breast cancer
2. Cancer of the breast
3. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel: A phase II study
4. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer
5. Patient preferences for oral versus intravenous palliative chemotherapy
6. A study of quality of life in cancer patients receiving palliative chemotherapy
7. A randomized crossover trial comparing oral UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer
8. 14C-labelled drug
9. Clinical pharmacokinetics of capecitabine
10. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
11. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
12. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
13. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
14. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients
15. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
16. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
17. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
18. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
19. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors
20. Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
21. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
22. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
23. Principles in the management of metastatic disease: Chemotherapy for metastatic disease
24. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial
25. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
26. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
27. Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer